Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
BPC-157 vs TB-500
An educational, source-based comparison of BPC-157 and TB-500 — how each peptide works, what it's researched for, and what to know before going deeper.
A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.
- Tendon-to-bone healing
- Ligament and muscle recovery
- Gastric ulcer protection
- Inflammatory bowel models
- Neuroprotection (rodent)
- • Human clinical trials are limited — most research is preclinical.
- • Not FDA-approved for human therapeutic use.
- • Quality, purity, and dosing of compounded peptides vary widely.
Synthetic fragment of Thymosin Beta-4 studied for tissue and vascular repair.
A synthetic peptide fragment of Thymosin Beta-4 (Tβ4). Research suggests it upregulates actin, promotes cell migration, angiogenesis, and modulates inflammation — supporting repair in muscle, tendon, cardiac, and corneal tissue models.
- Muscle and tendon repair
- Cardiac tissue recovery (preclinical)
- Corneal and dermal wound healing
- Hair follicle stem cell activation
- • Not FDA-approved; banned by WADA.
- • Most evidence is preclinical.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
3 cited studies; evidence base is growing.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| BPC-157 | Pentadecapeptide BPC 157 and the central nervous system | Neural Regeneration Research | 2022 | Review of neuroprotective and neurorepair signaling pathways observed in animal models. |
| BPC-157 | Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia/reperfusion in rats | Journal of Physiology - Paris | 2018 | Demonstrated mucosal protective effects and accelerated recovery from induced colitis. |
| BPC-157 | BPC 157 and tendon-to-bone healing | Journal of Orthopaedic Research | 2010 | Improved biomechanical recovery of transected Achilles tendons in rats. |
| TB-500 | Thymosin beta-4: a multi-functional regenerative peptide | Expert Opinion on Biological Therapy | 2015 | Review of Tβ4's roles in repair, angiogenesis, and anti-inflammation. |
Side-effect & safety grid
- Human clinical trials are limited — most research is preclinical.
- Not FDA-approved for human therapeutic use.
- Quality, purity, and dosing of compounded peptides vary widely.
- Not FDA-approved; banned by WADA.
- Most evidence is preclinical.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
BPC-157 vs TB-500 — Key differences
- Class: BPC-157 is classified as Tissue Repair · Gastrointestinal, while TB-500 is Tissue Repair · Vascular.
- Primary research focus: BPC-157 — tendon-to-bone healing; TB-500 — muscle and tendon repair.
- Tag: Recovery vs Recovery.
BPC-157 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tendon and ligament recovery (preclinical) | Rodent models (rat, mouse) | Subcutaneous or intraperitoneal | 10 mcg/kg/day | 10–14 days in most cited studies | Animal data only; cited human-grade safety or efficacy evidence is not established. |
| GI mucosal recovery (preclinical) | Rodent models | Oral or intragastric in some studies; subcutaneous in others | 10–50 mcg/kg/day depending on study | 5–14 days | Frequently cited in gut-recovery literature; remains preclinical. |
| Anecdotal human research-use (non-clinical literature) | Adults, mixed; off-label | Subcutaneous | Commonly cited 250–500 mcg, 1–2× daily | 2–6 week cycles in user reports | Not validated by controlled human trials; FDA has flagged BPC-157 outside approved drug pathways. |
BPC-157 Research — Female vs Male Studies
How published BPC-157 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Female-specific clinical trial data for BPC-157 are essentially absent. Preclinical rodent studies have included female animals but do not isolate sex-based outcomes.
- Female rodents in tissue-recovery models
- • No published human RCTs stratified by sex.
- • Pregnancy, lactation, and hormonal-cycle effects have not been characterized.
Male research
Male-specific clinical data are similarly limited. Most cited animal studies use male rodents for tendon, ligament, and GI models.
- Male rodents in tendon/ligament/GI repair models
- • No published human RCTs in men.
- • Anecdotal human use reports skew male but do not constitute clinical evidence.
BPC-157 — Frequently Asked Questions
Is BPC-157 FDA-approved?+
No. BPC-157 is not FDA-approved for any indication. It has appeared on the FDA's bulk-substance review lists as not eligible for traditional compounding under current evidence.
What does research suggest BPC-157 is studied for?+
Most cited BPC-157 research involves rodent models of tendon, ligament, and gastrointestinal mucosal recovery. Human controlled trial data remain very limited.
Are BPC-157 protocols the same for men and women?+
Published literature does not separate BPC-157 dosing by sex. There are no controlled human trials establishing sex-specific protocols.
TB-500 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tissue and wound recovery (preclinical) | Rodent and large-animal models | Subcutaneous or intramuscular | Equivalent of ~2 mg/kg in some animal models | Single doses to multi-week courses across studies | Cited in preclinical recovery and angiogenesis literature. |
| Cardiac and dermal recovery research (early human work) | Small early-phase human studies of thymosin beta-4 | Topical (dermal ulcers) or IV (cardiac research) | Topical formulations 0.01–0.1% in ulcer studies | Several weeks in dermal-ulcer trials | Early-phase research only; not an FDA-approved drug. |
| Anecdotal injectable use (off-label) | Adults, mixed; off-label | Subcutaneous | Commonly cited 2.0–2.5 mg, 1–2× per week in non-clinical reports | 4–6 week 'loading' phases described in user reports | Banned by WADA in athletes; not a validated clinical protocol. |
TB-500 Research — Female vs Male Studies
How published TB-500 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Published TB-500 / thymosin beta-4 research includes both sexes in dermal-ulcer and cardiac pilot studies, but female-specific endpoints are not isolated.
- Mixed-sex early-phase human dermal-ulcer studies
- • Pregnancy and lactation data are not established.
- • No sex-stratified outcomes reported in the cited literature.
Male research
Male-specific clinical data for TB-500 are limited to mixed-sex early-phase studies. Anecdotal recovery use reports skew male but are not controlled research.
- Mixed-sex early-phase human studies
- • No male-only TB-500 RCTs identified in the cited literature.
- • WADA prohibits TB-500 in competitive athletes year-round.
TB-500 — Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?+
TB-500 is the research name for a synthetic fragment closely related to thymosin beta-4 (TB-4), the naturally occurring 43-amino-acid peptide. The two terms are often used interchangeably in research literature, though formulations can differ.
Is TB-500 FDA-approved?+
No. TB-500 is not FDA-approved for any indication. Thymosin beta-4 has been studied in early-phase trials for dermal ulcers and cardiac recovery but is not an approved drug.
Why is TB-500 banned in athletes?+
TB-500 is on the World Anti-Doping Agency (WADA) prohibited list year-round as a non-specified prohibited substance, primarily on the basis of its tissue-recovery and angiogenic effects.